Breaking News Instant updates and real-time market news.

JNJ

Johnson & Johnson

$132.26

-0.34 (-0.26%)

14:23
07/17/17
07/17
14:23
07/17/17
14:23

On The Fly: What to watch in Johnson & Johnson earnings report

Johnson & Johnson (JNJ) is scheduled to report results of its fourth fiscal quarter before the market open on July 18, with a conference call scheduled for 8:30 am EDT. What to watch for: 1. UPBEAT GUIDANCE: Along with its last report, J&J raised its fiscal year 2017 earnings per share view to $7.00-$7.15 from S $6.93-$7.08, versus a consensus at the time of $7.05. Analysts currently see the company reporting EPS of $7.10 this fiscal year. On April 19, the day after J&J's Q1 earnings release, research firm UBS said that the company's quarterly EPS results were a "solid" beat. The firm raised its estimates to reflect the Actelion (ALIOF), deal which is expected to close in Q2. UBS reiterated its Buy rating and $136 price target on Johnson & Johnson shares. Another research firm, Leerink, weighed in on J&J earnings after its last report. Leerink analyst Danielle Antalffy lowered her price target for Johnson & Johnson to $140 from $150 on valuation. The analyst noted that the shares sold off as investors seemed taken aback by weakness in both non-REMICADE Pharma and Consumer, but she pointed out that there were a number of potential drivers for an improving outlook going forward, including Medical Devices growth reacceleration, continued strong double-digit growth of key new drugs, and likely consumer growth reacceleration as the macroeconomic environment improves. The analyst reiterated an Outperform rating on the shares. 2. TOUGH PHARMA ENVIRONMENT: According to a research paper from University of Pennsylvania, out in May, the pharmaceutical industry faces some critical challenges, including the decline in the discovery, approval and marketing of new chemical entities with fewer and fewer blockbuster drugs making it to the market, competition from generics drugs, regulatory pressures and the weak growth in the U.S. market and therefore the need to explore other markets, to name a few. Recently, JPMorgan analyst Michael Weinstein noted the difficult conditions for pharma and their potential impact on J&J's Q2 results." J&J is coming off a disappointing Q1, and Q2 is going to be just as challenging, owing to $340M in Q2 of 2016 gross-to-net adjustments that make for a particularly tough comp. As a result, Q2 is likely to look a lot like the first," wrote Weinstein in a note out in early May. JP Morgan analyst Weinstein and his team called attention to the fact that J&J shares underperformed due to "the prospect of decelerating top-line growth in 2017, owing to increased competition for the Pharmaceutical business. According to JP Morgan's Weinstein deceleration should abate after the current quarter, which him to raise his rating to Overweight and price target to $140 on J&J shares. ACTELION ACQUISITION: In late January, J&J announced it was acquiring Switzerland-based Actelion. Actelion has a "strong" history of innovation to discover and develop new and differentiated products in multiple therapeutic areas, J&J said in a press release on January 26. Actelion has developed oral, inhaled and intravenous formulations of compounds to treat patients at various stages of pulmonary arterial hypertension. It is also developing therapies for multiple sclerosis, digital ulcers, Niemann-Pick type C disease, Gaucher disease, a lymphoma known as mycosis fungoides, and infectious diseases such as Clostridium difficile-associated diarrhea. The transaction closed on June 16 and will now become part of the Janssen Pharmaceutical Companies of Johnson & Johnson. Johnson & Johnson expects the transaction to add approximately $1.3B in sales for 2017 and be accretive to 2017 adjusted EPS by approximately 7c. This impact was already included in the company's full-year sales and adjusted EPS guidance provided in April. Also, as previously disclosed, in the first full year after close, Johnson & Johnson expects the transaction to be accretive to adjusted EPS by 35c-40c.

  • 18

    Jul

  • 09

    Aug

JNJ Johnson & Johnson
$132.26

-0.34 (-0.26%)

07/14/17
WELS
07/14/17
NO CHANGE
WELS
Underperform
J&J approval another negative for Valeant, says Wells Fargo
Wells Fargo analyst David Maris says Valeant Pharmaceuticals (VRX) has a new competitor in the psoriasis space after the FDA yesterday approved Tremfya from Johnson & Johnson (JNJ). The news is another negative for Valeant, which is about to launch its own psoriasis treatment, Siliq, in the second half of 2017, Maris tells investors in a research note. With Talz from Eli Lilly (LLY), Humira from AbbVie (ABBV), Cosentyx from Novartis (NVS) and now J&J as a new competitor, Valeant is unlikely to be competitive in the psoriasis market, Maris contends. He believes his peak sales estimate of $250M for Siliq may prove optimistic given the competition. Maris an Underperform rating on Valeant with a $9 price target. The drugmaker closed yesterday at $17.29.
06/27/17
06/27/17
NO CHANGE

Large cap pharma could benefit from upcoming executive order, says Wells Fargo
Wells Fargo says that, based on press reports, large cap pharma could benefit from President Trump's upcoming executive order on drug pricing. The firm says the articles indicate that the order will not create major reforms or do anything to lower consumers' costs or solve current pricing issues. Publicly traded companies in the space include AstraZeneca (AZN), Bristol-Myers (BMY), Eli Lilly (LLY), GlaxoSmithKline (GSK), Johnson & Johnson (JNJ), Merck (MRK), Novartis (NVS), Pfizer (PFE), Roche (RHHBY) and Sanofi (SNY).
06/20/17
ADAM
06/20/17
NO CHANGE
Target $10
ADAM
Buy
Novadaq competing bids possible if not probable, says Canaccord
Canaccord analyst Jason Mills noted Novadaq (NVDQ) received an acquisition offer from Stryker (SYK) at a much greater equity value than what the company was trading at prior to the bid. Although he thinks Stryker is the most logical buyer of the franchise, he thinks there are several other potential acquirers, including Medtronic (MDT), Johnson & Johnson (JNJ) and Intuitive Surgical (ISRG), in that order. Mills believes this is a good exit for the company and that Stryker is getting a good asset. Mills maintains his Buy rating and $10 price target on Novadaq shares.
06/14/17
RHCO
06/14/17
NO CHANGE
RHCO
Eli Lilly has positive read through from J&J data, says SunTrust
SunTrust analyst John Boris says that data for Johnson & Johnson's (JNJ) Invokana for diabetes represented a best-case scenario for Eli Lilly (LLY). J&J's drug "significantly reduced the combined risk of cardiovascular death, myocardial infarction and nonfatal stroke in diabetes patients at risk for or with a history of CV diseases," and its efficacy on CV death is positive for the SGLT-2 class, to which Eli Lilly's Jardiance also belongs, according to the analyst. But the data leaves Jardiance, which reduced CV death by a statistically significant 38% versus Invokana's non-significant 13%, as the best in the class, wrote the analyst, who reiterates a $101 price target and a Buy rating on Eli Lilly.

TODAY'S FREE FLY STORIES

ACRS

Aclaris Therapeutics

$29.18

-0.46 (-1.55%)

04:55
07/28/17
07/28
04:55
07/28/17
04:55
Conference/Events
Aclaris Therapeutics management to meet with Jefferies »

Meeting to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Jul

04:55
07/28/17
07/28
04:55
07/28/17
04:55
General news
Breaking General news story  »

Week of 7/28 Baker-Hughes…

04:55
07/28/17
07/28
04:55
07/28/17
04:55
General news
Consumer Sentiment Index to be reported at 10:00 »

Consumer Sentiment Index…

JAGX

Jaguar Animal Health

$0.66

-0.0175 (-2.58%)

04:55
07/28/17
07/28
04:55
07/28/17
04:55
Conference/Events
Jaguar Animal Health to hold a conference call »

Conference call to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Jul

04:55
07/28/17
07/28
04:55
07/28/17
04:55
General news
GDP price index to be reported at 08:30 »

GDP price index will be…

CALM

Cal-Maine Foods

$38.05

0.55 (1.47%)

04:55
07/28/17
07/28
04:55
07/28/17
04:55
Conference/Events
Cal-Maine Foods participates in a conference call with Stephens »

Stephens hosts a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Jul

04:55
07/28/17
07/28
04:55
07/28/17
04:55
General news
Real GDP to be reported at 08:30 »

Real GDP will be reported…

BAESY

BAE Systems

$32.23

0.145 (0.45%)

, IBM

IBM

$145.07

-0.29 (-0.20%)

04:55
07/28/17
07/28
04:55
07/28/17
04:55
Conference/Events
RSA Security to hold a conference »

RSA Security Conference…

BAESY

BAE Systems

$32.23

0.145 (0.45%)

IBM

IBM

$145.07

-0.29 (-0.20%)

CTL

CenturyLink

$23.60

0.74 (3.24%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 02

    Aug

  • 08

    Aug

04:55
07/28/17
07/28
04:55
07/28/17
04:55
General news
Breaking General news story  »

Minneapolis Federal…

04:55
07/28/17
07/28
04:55
07/28/17
04:55
General news
Employment Cost Index ECI to be reported at 08:30 »

Employment Cost Index ECI…

03:35
07/28/17
07/28
03:35
07/28/17
03:35
General news
FX Action: USD-CAD steady after posting its biggest one-day gain »

FX Action: USD-CAD steady…

01:40
07/28/17
07/28
01:40
07/28/17
01:40
General news
FX Update: The Swiss franc tumbled for a four straight session »

FX Update: The Swiss…

TOO

Teekay Offshore Partners

$2.55

-0.03 (-1.16%)

20:27
07/27/17
07/27
20:27
07/27/17
20:27
Downgrade
Teekay Offshore Partners rating change at Raymond James »

Teekay Offshore…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

QEP

QEP Resources

$7.93

-1.34 (-14.46%)

20:26
07/27/17
07/27
20:26
07/27/17
20:26
Downgrade
QEP Resources rating change at JPMorgan »

QEP Resources downgraded…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Jul

  • 14

    Aug

RDFN

Redfin

20:26
07/27/17
07/27
20:26
07/27/17
20:26
Syndicate
Redfin 9.231M share IPO priced at $15.00 »

The deal range is…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Jul

  • 28

    Jul

XOM

Exxon Mobil

$80.83

0.46 (0.57%)

, CVX

Chevron

$106.11

0.99 (0.94%)

20:25
07/27/17
07/27
20:25
07/27/17
20:25
Earnings
Notable companies reporting before tomorrow's open »

Notable companies…

XOM

Exxon Mobil

$80.83

0.46 (0.57%)

CVX

Chevron

$106.11

0.99 (0.94%)

MRK

Merck

$63.69

1.89 (3.06%)

ABBV

AbbVie

$71.73

-0.86 (-1.18%)

AAL

American Airlines

$50.00

-1.01 (-1.98%)

COL

Rockwell Collins

$109.02

-0.53 (-0.48%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Jul

  • 28

    Jul

  • 28

    Jul

  • 28

    Jul

  • 28

    Jul

  • 28

    Jul

  • 07

    Aug

  • 28

    Aug

  • 22

    Sep

TTPH

Tetraphase

$6.96

-0.92 (-11.68%)

20:22
07/27/17
07/27
20:22
07/27/17
20:22
Syndicate
Tetraphase 10M share Secondary priced at $6.50 »

Piper Jaffray, BMO…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Jul

BVN

Buenaventura

$12.45

0.1 (0.81%)

19:26
07/27/17
07/27
19:26
07/27/17
19:26
Earnings
Buenaventura reports Q2 EPS (2c), may not compare to consensus 26c »

Reports Q2 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

BAS

Basic Energy

$28.67

0.06 (0.21%)

19:02
07/27/17
07/27
19:02
07/27/17
19:02
Hot Stocks
Breaking Hot Stocks news story on Basic Energy »

Basic Energy backs FY17…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Jul

  • 14

    Aug

BAS

Basic Energy

$28.67

0.06 (0.21%)

19:01
07/27/17
07/27
19:01
07/27/17
19:01
Earnings
Basic Energy reports Q2 adjusted EPS (57c), consensus (55c) »

Reports Q2 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Jul

  • 14

    Aug

GE

General Electric

$25.79

0.2 (0.78%)

18:55
07/27/17
07/27
18:55
07/27/17
18:55
Periodicals
Breaking Periodicals news story on General Electric »

Uber CEO shortlists…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 02

    Oct

AIV

Aimco

$44.01

0.13 (0.30%)

18:53
07/27/17
07/27
18:53
07/27/17
18:53
Earnings
Aimco reports Q2 AFFO 51c vs 50c last year »

Reports Q1 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Jul

NOV

National Oilwell

$33.71

0.37 (1.11%)

18:43
07/27/17
07/27
18:43
07/27/17
18:43
Earnings
National Oilwell reports Q2 adjusted EPS (14c), consensus (15c) »

Reports Q2 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Jul

  • 29

    Aug

AIG

AIG

$65.17

-0.02 (-0.03%)

, IEP

Icahn Enterprises

$53.12

-0.78 (-1.45%)

18:39
07/27/17
07/27
18:39
07/27/17
18:39
Periodicals
Senators worried over whether Icahn is pushing regulators on AIG, Reuters says »

U.S. Democratic Senators…

AIG

AIG

$65.17

-0.02 (-0.03%)

IEP

Icahn Enterprises

$53.12

-0.78 (-1.45%)

PRU

Prudential

$112.74

0.55 (0.49%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 03

    Aug

  • 03

    Aug

  • 27

    Sep

HTBK

Heritage Commerce

$13.85

-0.14 (-1.00%)

18:24
07/27/17
07/27
18:24
07/27/17
18:24
Earnings
Heritage Commerce reports Q2 EPS 19c, consensus 19c »

Reports Q2 NII $24.9M,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 01

    Aug

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.